Skip to content

Study · Randomized controlled trial · 2025

11 results

Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.

Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, Lou J, Hartman ML, Martin CK, Coskun T

Diabetes, obesity & metabolism8 Sept 2025Cited by 1 (Europe PMC)

PMID40916752 (opens in a new tab)PMCIDPMC12587234 (opens in a new tab)DOI10.1111/dom.70097 (opens in a new tab)PepBankPUB-40916752
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, retatrutide at 4 mg or more reduced overall appetite from baseline more than placebo at week 24.

    In plain wordsIn adults with type 2 diabetes, retatrutide at 4 mg or more lowered overall appetite more than placebo at week 24.

    Peptide
    Retatrutide
    Outcome
    DecreaseOverall appetite (VAS) at week 24
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    >=4 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, participants who received retatrutide ≥4 mg reported greater reductions from baseline in overall appetite, hunger, and prospective food consumption
    2 context sentences
    Summary · context
    at Week 24 (all p <0.05)).
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, retatrutide at 4 mg or more reduced hunger from baseline more than placebo at week 24.

    In plain wordsIn adults with type 2 diabetes, retatrutide at 4 mg or more lowered hunger more than placebo at week 24.

    Peptide
    Retatrutide
    Outcome
    DecreaseHunger (VAS) at week 24
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    >=4 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, participants who received retatrutide ≥4 mg reported greater reductions from baseline in overall appetite, hunger, and prospective food consumption
    2 context sentences
    Summary · context
    at Week 24 (all p <0.05)).
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, retatrutide at 4 mg or more reduced prospective food consumption from baseline more than placebo at week 24.

    In plain wordsIn adults with type 2 diabetes, retatrutide at 4 mg or more lowered expected food intake more than placebo at week 24.

    Peptide
    Retatrutide
    Outcome
    DecreaseProspective food consumption (VAS) at week 24
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    >=4 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, participants who received retatrutide ≥4 mg reported greater reductions from baseline in overall appetite, hunger, and prospective food consumption
    2 context sentences
    Summary · context
    at Week 24 (all p <0.05)).
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, differences between retatrutide and dulaglutide in appetite measures were less consistent than differences versus placebo.

    In plain wordsIn adults with type 2 diabetes, appetite differences between retatrutide and dulaglutide were less consistent than differences from placebo.

    Peptide
    Retatrutide
    Outcome
    MixedAppetite measures versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide 1.5 mg
    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Differences versus dulaglutide were less consistent.
    1 context sentence
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, retatrutide 8 and 12 mg improved Eating Inventory Perceived Hunger from baseline more than placebo at weeks 24 and 36.

    In plain wordsIn adults with type 2 diabetes, retatrutide 8 and 12 mg reduced perceived hunger more than placebo at weeks 24 and 36.

    Peptide
    Retatrutide
    Outcome
    DecreaseEating Inventory Perceived Hunger
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    8 and 12 mg · 24 and 36 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements from baseline versus placebo in EI Perceived Hunger and Disinhibition were greater in participants who received retatrutide 8 and 12 mg at Weeks 24 and 36.
    1 context sentence
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, retatrutide 8 and 12 mg improved Eating Inventory Disinhibition from baseline more than placebo at weeks 24 and 36.

    In plain wordsIn adults with type 2 diabetes, retatrutide 8 and 12 mg reduced the tendency to overeat more than placebo at weeks 24 and 36.

    Peptide
    Retatrutide
    Outcome
    DecreaseEating Inventory Disinhibition
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    8 and 12 mg · 24 and 36 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements from baseline versus placebo in EI Perceived Hunger and Disinhibition were greater in participants who received retatrutide 8 and 12 mg at Weeks 24 and 36.
    1 context sentence
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, Dietary Restraint increased from baseline versus placebo only with retatrutide 12 mg at week 36.

    In plain wordsIn adults with type 2 diabetes, conscious limiting of food intake rose more than with placebo only with retatrutide 12 mg at week 36.

    Peptide
    Retatrutide
    Outcome
    IncreaseEating Inventory Dietary Restraint at week 36
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    12 mg · 36 weeksAs given in this study (human).

    Source sentences

    Summary
    Dietary Restraint increased from baseline versus placebo only in participants who received retatrutide 12 mg at Week 36 (all p <0.05).
    1 context sentence
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on retatrutide, reductions in Perceived Hunger correlated significantly with body weight reductions at week 36 (post-hoc).

    In plain wordsIn adults with type 2 diabetes on retatrutide, lower perceived hunger was linked to more weight loss at week 36.

    Peptide
    Retatrutide
    Outcome
    Not applicableCorrelation of Perceived Hunger reduction with weight reduction
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 36 weeksAs given in this study (human).

    Measurements

    Correlation r
    0.28
    Perceived Hunger vs body weight, week 36

    Source sentences

    Summary
    Reductions in Perceived Hunger and Disinhibition, and increases in Dietary Restraint were significantly correlated with reductions in body weight at Week 36 (r = 0.28, r = 0.36, and r = 0.31, respectively).
    1 context sentence
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on retatrutide, reductions in Disinhibition correlated significantly with body weight reductions at week 36 (post-hoc).

    In plain wordsIn adults with type 2 diabetes on retatrutide, less tendency to overeat was linked to more weight loss at week 36.

    Peptide
    Retatrutide
    Outcome
    Not applicableCorrelation of Disinhibition reduction with weight reduction
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 36 weeksAs given in this study (human).

    Measurements

    Correlation r
    0.36
    Disinhibition vs body weight, week 36

    Source sentences

    Summary
    Reductions in Perceived Hunger and Disinhibition, and increases in Dietary Restraint were significantly correlated with reductions in body weight at Week 36 (r = 0.28, r = 0.36, and r = 0.31, respectively).
    1 context sentence
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on retatrutide, increases in Dietary Restraint correlated significantly with body weight reductions at week 36 (post-hoc).

    In plain wordsIn adults with type 2 diabetes on retatrutide, more conscious limiting of food intake was linked to more weight loss at week 36.

    Peptide
    Retatrutide
    Outcome
    Not applicableCorrelation of Dietary Restraint increase with weight reduction
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 36 weeksAs given in this study (human).

    Measurements

    Correlation r
    0.31
    Dietary Restraint vs body weight, week 36

    Source sentences

    Summary
    Reductions in Perceived Hunger and Disinhibition, and increases in Dietary Restraint were significantly correlated with reductions in body weight at Week 36 (r = 0.28, r = 0.36, and r = 0.31, respectively).
    1 context sentence
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.
  11. 11HumanNon-randomized trialEfficacy outcome

    In adults with T2D, differences between higher-dose retatrutide and dulaglutide in appetite and eating-behaviour scores were less consistent, although the plain-language summary reported less hunger and overeating with higher-dose retatrutide than with dulaglutide.

    In plain wordsIn adults with diabetes, appetite differences between higher-dose retatrutide and dulaglutide were less consistent.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedHunger and overeating (appetite and eating behaviour scores)
    Study

    n: not reported in source

    Comparator
    Higher-dose retatrutide
    Analysis
    Exploratory
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 36 weeksAs given in this study (human).

    Source sentences

    Summary
    Differences versus dulaglutide were less consistent.
    Summary
    This study showed that adults with type 2 diabetes who received higher doses of retatrutide reported being less likely to feel hungry or overeat compared to those who received no treatment (i.e., placebo) or those who received dulaglutide.
    1 context sentence
    Summary · context
    These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 8Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    9 Oct 2026, 19:08 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.